SILVER SPRING
Imfinzi cleared for BCG-naïve high-risk non-muscle-invasive bladder cancer
- Sponsor
- AstraZeneca $AZN
- Drug
- Imfinzi · durvalumab
- Indication
- BCG-naïve, high-risk non-muscle-invasive bladder cancer
FDA approved AstraZeneca's Imfinzi in combination with BCG induction and maintenance therapy for BCG-naïve, high-risk non-muscle-invasive bladder cancer.
What this means
Imfinzi (durvalumab) is an immunotherapy drug that helps the immune system recognize and attack bladder cancer cells by blocking a protein called PD-L1. The FDA cleared Imfinzi for use alongside BCG therapy in patients with high-risk bladder cancer who haven’t received BCG treatment before. This approval gives doctors a new option for patients who may need stronger treatment to prevent cancer recurrence.
Drug Watch — recent news on Imfinzi
- MATTERHORN Sets New Standard in Gastric Cancer - Targeted Oncology
- Imfinzi Plus Chemotherapy Raises 3-Year Survival to 69% in Gastric Cancer - Cure Today
- TOURMALINE - Durvalumab Safety with Gemcitabine-Based Chemotherapy Backbones - CancerNetwork
- MATTERHORN: Durvalumab Plus FLOT Improves OS in Resectable Gastric and GEJ Adenocarcinoma - Oncodaily
- MTD-BRIDGE: Curative-Intent Therapy Rates High With Durvalumab Plus Chemo in Resectable, Borderline Resectable NSCLC - Cancer Therapy Advisor